Replay available

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2024 Earnings Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Q1 2024 earnings conference call, held 2024-05-09. Replay captured from the company's public earnings webcast.

Thu, May 9, 2024 at 8:30 AMendedReplay
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2024 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Matt Roach

Director of Investor Relations

Tom McCourt

Chief Executive Officer

Mike Schetzlein

Chief Medical Officer

Shravan Imani

Chief Financial Officer

David Amsalem

Analyst at Piper Sandler

Chase Meeker-Bucker

Analyst at Craig Hallum

Amy Lee

Analyst at Jefferies

Jason Butler

Analyst at Citizens J&B

Mohit Bansal

Analyst at Wells Fargo

Tim Chiang

Analyst at Capital One Securities

Replay transcript excerpt

Thank you for standing by. My name is Cath and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals first quarter 2024 investor update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Matt Roach, Director of Industrial Relations. Please go ahead. Thank you, Cass. Good morning and thanks for joining us for our first quarter 2024 investor update. Our press release issued this morning can be found on our website. Today's call and accompanying slides include four looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties and may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current Safe Harbor Statement slide, as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2023, and in our subsequent SEC filings. All four looking statements speak as of the date of this presentation. We undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement and not a substitute for or superior to GATT measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GATT measures. During today's call, Tom McCourt, our...

More from Ironwood Pharmaceuticals, Inc.